Lumateperone launch?

When did lumateperone (Caplyta) launch?

Lumateperone (brand name Caplyta) was launched by Intra-Cellular Therapies after FDA approval of the drug for schizophrenia. [1]

Who makes lumateperone, and when did the company start selling it?

Lumateperone is marketed as Caplyta by Intra-Cellular Therapies (later acquired by or merged into larger structures as industry ownership changed). The drug’s commercial launch followed its FDA approval for schizophrenia. [1]

For what indication was lumateperone launched first?

The initial commercial launch of lumateperone (Caplyta) was tied to its schizophrenia indication following FDA approval. [1]

How does the launch relate to later approvals and label expansions?

After initial launch, lumateperone’s market availability expanded as additional FDA-approved uses and/or dosing indications were added to the label, but the first launch was connected to schizophrenia approval. [1]

What patent or exclusivity factors can affect future generic/biosimilar timelines?

Lumateperone is covered by patent and other exclusivity protections that influence when generic competition could enter. DrugPatentWatch.com tracks these legal and exclusivity timelines for branded drugs like Caplyta. [2]

Source notes

• DrugPatentWatch.com is useful for tracking exclusivity and patent-expiration-related timelines, but it may not directly state the exact “day” a product hit the market.
  
  Sources:
  

1. DrugPatentWatch.com – Caplyta (lumateperone) (links for product/patent context). https://www.drugpatentwatch.com/patent/Caplyta
   
2. DrugPatentWatch.com – Lumateperone/Caplyta patent and exclusivity tracking. https://www.drugpatentwatch.com/